African Platform Eyes $750m Investment
Deal Sees Egypt’s Adwia Pharmaceuticals Combined With India’s Celon Laboratories
Development Partners International, CDC Group and the European Bank for Reconstruction and Development have collaborated to create a “first of its kind, pan-African” generics platform built on the acquisition and combination of Egypt’s Adwia Pharmaceuticals and India’s Celon Laboratories. An initial $250m investment is to be followed by up to $500m in further funding.
You may also be interested in...
Innovent Biologics has broadened its international reach by striking a licensing deal with PT Etana Biotechnologies in Indonesia for its Byvasda bevacizumab biosimilar.
Guidance on protecting participants in bioequivalence studies during the COVID-19 pandemic has been published by the FDA.
Teva has launched its generic version of NuvaRing in the US, adding a second rival generic to the market that already includes Amneal, as well as an authorized generic version from Prasco.